Omada Health Inc. (OMDA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$19.65 +2.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.70

Omada Health Inc. (OMDA) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.20B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $19.70 (+0.25%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 6.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510056
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+
Cash (13)Whales (10)SEC (16)Macro (11)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
$27 Bull$19 Base$15 Bear
📬 FREE OMDA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OMDA)Realized 20D OHLCV Swing Band: ±11.2%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY OMDA SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (29% of score)

Altman Z-Score 8.93 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 6.5% FCF Margin ($16.9M FCF) & 65.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$21.55-18.2% Next Q
Q2 (-2Q)
61
Grade C$17.63+7.5% Next Q
Q3 (-1Q)
59
Grade C$18.95+3.7% Next Q
Current
56
Grade D+$19.65-0.4% Hist 90D α
Trajectory: C+ (64) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the OMDA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, OMDA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 63.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.75) or 200D SMA ($17.68) invalidates the momentum regime and cuts Target Base ($19.47) toward Bear Floor ($15.19).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OMDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OMDA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

OMDA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (OMDA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on OMDA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OMDA)

  • ✓Walkthrough of OMDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OMDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.77%📐 HORIZONTAL RANGE
2026-10-30O $19.35H $19.65L $18.47C $19.65VOL 958.6K
RES: $26.98SUP: $17.34SMA50: $20.75SMA200: $17.68
$26.30$22.77$19.23$15.70$12.16RES $26.98SUP $17.34$19.652026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OMDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OMDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OMDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OMDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OMDA)

Health Care Rank #264 of 1016 ⚔️ INNV vs OMDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OMDA vs. INNV, USPH, PNTG, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Omada Health Inc. (OMDA) ranks #264 by composite RQD confidence (56/100, grade D+) and #338 by equity capitalization ($1.20B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with OMDA at 56/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OMDA ACTIVE
Omada Health Inc.
D+ 56/100 — 65.7% -15.7% +2.45% $1.20B Benchmark Subject
INNV
InnovAge Holding Corp.
D+ 57/100 — 18.0% -10.2% +1.54% $1.26B /innv-vs-omda →
USPH
U.S. Physical Therapy Inc.
C 64/100 32.6x 19.2% 11.5% +1.47% $1.29B /usph-vs-omda →
PNTG
The Pennant Group Inc.
D+ 56/100 50.2x — 11.0% +0.76% $1.48B /pntg-vs-omda →
TDOC
Teladoc Health Inc.
D+ 56/100 — — -17.0% +26.89% $1.59B /tdoc-vs-omda →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001611115

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Omada Health Inc. (OMDA) reported GAAP revenue of $260.2M (+53.2% vs. FY2024 revenue of $169.8M , and +111.9% cumulative change since FY2023) , GAAP net income of -$12.8M, operating cash flow of $18.3M, and free cash flow of $16.9M (+148.7% YoY). On the balance sheet, OMDA closed FY2025 with $305.4M in total assets against $0 in total debt (Altman Z-Score: 8.93, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $260.2M -$12.8M $18.3M $16.9M $305.4M —
FY2024 (FY) 2024-12-31 $169.8M -$47.1M -$34.2M -$34.8M $150.9M —
FY2023 (FY) 2023-12-31 $122.8M -$67.5M -$49.7M -$49.7M — —

3. OMDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Omada Health Inc. (NASDAQ: OMDA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $19.65 (+2.45% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, OMDA ranks #264 in composite RQD confidence.

How does OMDA compare to INNV and USPH in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), OMDA carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -15.7%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -10.2%, cap $1.26B) and USPH (U.S. Physical Therapy Inc.) posts a C grade (64/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.29B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OMDA?

Per OMDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611115), Omada Health Inc. generated $260.2M in revenue (+53.2% YoY), -$12.8M in net income, and $16.9M in free cash flow against $305.4M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OMDA trading relative to its 50-day, 200-day, and 52-week technical levels?

OMDA last traded at $19.65 (+2.45% on volume of 620,107 shares), positioning the stock -5.30% below its 50-day simple moving average ($20.75) and +11.14% above its 200-day simple moving average ($17.68). Across its 52-week range of $10.28 to $26.13, OMDA sits at the 59.1% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($17.45 to $21.85).

OMDA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are OMDA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies OMDA leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%